Amgen's fast-growing cancer immunotherapy Imdelltra could move into the first-line setting in small cell lung cancer (SCLC), ...

The pivotal QUINTESSENTIAL trial of the potentially first-in-class CAR-T showed a "statistically significant and clinically ...

The FDA has started a priority review of AstraZeneca's IL-33-targeting antibody tozorakimab for chronic obstructive pulmonary ...

An AI-powered imaging tool developed by Brainomix has been used to enrich data from a phase 2a trial of Endeavor BioMedicines ...

Registration and the full programme are available on the DIA-MHRA Global Summit page. Follow the conversation at ...

Every few years, drug development goes through a moment where a new technology promises to change everything. Artificial ...

Different regions have distinct healthcare systems, varying access levels, reimbursement models, and treatment realities — ...

Hippocratic AI has expanded its focus with the acquisition of Grove AI, a specialist in AI used in pharma R&D, to complement its current activities in patient-facing, generative AI (GenAI) agents.

Anglo-Swiss life sciences investment company Medicxi has raised €500 million (around $579 million) for its sixth fund, which will focus on supporting 'asset-centric' companies at all stages of drug ...

Sobi's $1.5 billion takeover of Arthrosi at the end of 2025 has started to pay off, with a positive phase 3 trial for gout therapy pozdeutinurad, the main asset in the deal. The oral, once-daily URAT1 ...

Roche's oral selective oestrogen receptor degrader (SERD) giredestrant has achieved what the company says is a stellar result in an early breast cancer trial, building on earlier data in more advanced ...

Sanofi bids to add a drug candidate for Alzheimer's disease to its neurology pipeline via the acquisition of US biotech Vigil Neuroscience in a deal valued at $470 million. The $8-per-share deal will ...